论文部分内容阅读
目的探讨他汀类药物在脑卒中一级预防和二级预防中的效果及安全性。方法检索PubMed(1966—2006)、Cochrane图书馆(2006年第1期)、中国知识资源总库(1979—2006)及中文科技期刊数据库(1989—2006),获取并评价有关他汀类药物预防脑卒中的系统评价、Meta分析及随机对照试验。结果关于他汀类药物用于脑卒中的一级预防共检索到4篇Meta分析、8篇随机对照试验;关于脑卒中的二级预防共检索到1篇Cochrane系统评价和一项正在进行的随机对照试验。结论他汀类药物有望降低脑卒中的发生率,尤其对合并有冠心病、高血压、高血脂、糖尿病等脑血管病高危人群作用更为明显,在脑卒中的一级预防中有较为肯定的效果,且不增加出血性卒中和肿瘤的发生率;关于他汀类药物在脑卒中二级预防中的效果,目前高质量的临床证据尚不足,正在进行的卒中试验将为他汀类药物在脑卒中二级预防中的作用提供重要信息。
Objective To investigate the efficacy and safety of statins in primary prevention and secondary prevention of stroke. Methods PubMed (1966-2006), Cochrane Library (2006 issue 1), China Knowledge Resources Database (1979-2006) and Chinese Science and Technology Periodical Database (1989-2006) were searched in order to obtain and evaluate the effects of statin preventive brain Stroke Systematic Review, Meta Analysis and Randomized Controlled Trials. Results A total of 4 meta-analyzes and 8 randomized controlled trials were found on the primary prevention of statin use in stroke. Secondary prevention of stroke included 1 Cochrane systematic review and one ongoing randomized controlled trial test. Conclusions Statins are expected to reduce the incidence of stroke, especially for those at high risk of cerebrovascular disease such as coronary heart disease, hypertension, hyperlipidemia and diabetes mellitus, and have a positive effect in the primary prevention of stroke. , And does not increase the incidence of hemorrhagic stroke and tumor; the current high-quality clinical evidence of the effect of statins in secondary prevention of stroke is not enough and the ongoing stroke trial will provide statins for stroke in stroke II The role of prevention in class provides important information.